RetinaCME
CLINICAL CASECMEABO MOC

Optimizing Anti-VEGF Dosing for Improved Long-term Outcomes – A Look at the Latest Data

Author(s)/Faculty: Michael S. Ip, MD; Rishi P. Singh, MD; Nathan C. Steinle, MD
Release Date: 4/17/2020Expiration Date: 4/16/2021
Credit Type: CME / ABO MOCNumber of Credits: 0.75
Content Type: LectureProvider:
Intravitreal therapy has rapidly evolved to become a mainstay of treatment for many retinal diseases, and offers many patients delayed or arrested disease progression and the possibility of regaining lost vision. The treatment of neovascular AMD (nAMD) has been revolutionized by intravitreal anti-VEGF therapy. However, long-term extensions of major clinical trials have not demonstrated great success in maintaining the dramatic vision gains obtained initially, particularly when PRN dosing was used. Fixed-interval or treat-and-extend protocols, which generally use more frequent injections, have had greater success. In this educational activity, expert clinicians will assess the latest clinical evidence regarding anti-VEGF injection protocols to optimize long-term outcomes and will also evaluate the latest understanding regarding the effect of retinal fluid on visual outcomes in patients with nAMD.